On the 28th of June, 2019, the annual general meeting of the specialty pharma company ‘Hemogenyx Pharmaceuticals plc’ was held at the One London Wall at 11 am.
On a show of hands, there was conductance of voting of all of the resolution. They were all passed. The complete text for every resolution is set out in the notification of the meeting which is available on the website of the firm.
The number of proxy votes accordingly wedged before the meeting are set out and are also available at the firm’s website.
The issued share capital of the firm on the 28th of May, being the data at which the members had to tap into the register of the member s of the firm so that they could be entitled to attend, as well as, vote at the meeting, was 360,176,186 normal shares.
Any ‘vote withheld’ with regards to any resolution is not considered a vote in law and is not included in the calculation of the ratio of votes in the favor or against of it.
About the company
Hemogenyx Pharmaceuticals plc is a renowned traded company. It has its headquarter in London, with its completely owned United States operating subsidiaries, Hemogenyx LLC & Immugenyx LLC, situated in New York City at its modern research facility and a completely owned Belgian operating subsidiary, Hemogenyx Cell SPRL.
Hemogenyx Pharmaceuticals plc is a pre-clinical stage biopharma group creating new medicines & treatments to bring the curative power of bone marrow transplantation to a vast number of patients who are suffering from otherwise incurable deadly and life-threatening diseases. Hemogenyx is creating two unique and complementary products, as well as, a platform technology which is employed as an engine for new product development.